Emcure Pharmaceuticals Limited (BOM:544210)
India · Delayed Price · Currency is INR | Market Cap | 323.29B +64.5% |
| Revenue (ttm) | 92.04B +16.6% |
| Net Income | 9.24B +35.7% |
| EPS | 48.77 +33.9% |
| Shares Out | n/a |
| PE Ratio | 34.97 |
| Forward PE | 28.36 |
| Dividend | 3.00 (0.18%) |
| Ex-Dividend Date | Aug 14, 2025 |
| Volume | 3,702 |
| Open | 1,759.90 |
| Previous Close | 1,724.30 |
| Day's Range | 1,676.05 - 1,759.90 |
| 52-Week Range | 1,230.00 - 1,830.35 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 1,891.83 (+11.95%) |
| Earnings Date | May 5, 2026 |
About Emcure Pharmaceuticals
Emcure Pharmaceuticals Limited provide quality and affordable healthcare solutions worldwide. It offers products in various therapeutic areas, such gynecology, anti-infectives, pain/analgesics, Vitamins, Minerals & Nutrients, blood-related, oncology, respiratory, HIV antivirals, gastro, anti-diabetic, neuro, and cardiovascular. It provides its products under Orofer XT, Tenectase, Pause, Metpure XL, Vylda, Vitanova, and Proxym brand names. Emcure Pharmaceuticals Limited has a strategic partnership with Novo Nordisk India Pvt Ltd. for the develop... [Read more]
Financial Performance
In fiscal year 2026, Emcure Pharmaceuticals's revenue was 92.04 billion, an increase of 16.56% compared to the previous year's 78.96 billion. Earnings were 9.24 billion, an increase of 35.67%.
Financial StatementsNews
Emcure Pharmaceuticals Transcript: Q4 25/26
FY 2026 saw 16.6% revenue growth, 41% adjusted PAT growth, and margin expansion, driven by strong international and resilient domestic performance. FY 2027 guidance is for low-to-mid-teen revenue growth and further margin gains, with Zuventus integration stabilizing.
Emcure Pharmaceuticals Quarterly report: Q4 2026
Emcure Pharmaceuticals has published its Q4 2026 quarterly earnings report on May 5, 2026.
Emcure Pharmaceuticals Slides: Q4 2026
Emcure Pharmaceuticals has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on May 5, 2026.
Emcure Pharmaceuticals Transcript: Q3 25/26
Q3 FY26 saw 20.4% revenue growth and 48% PAT increase, driven by strong domestic and international performance, strategic in-licensing, and new launches like semaglutide. EBITDA margin improved to 19.5%, with a positive outlook for sustained growth and margin expansion.
Emcure Pharmaceuticals Quarterly report: Q3 2026
Emcure Pharmaceuticals has published its Q3 2026 quarterly earnings report on February 4, 2026.
Emcure Pharmaceuticals Transcript: Q2 25/26
Q2 FY2026 saw 13% revenue growth and record profits, driven by strong domestic and international performance. Strategic moves included a Novo Nordisk partnership for Semaglutide and full Zuventus acquisition, with margin and debt targets updated following recent M&A.
Emcure Pharmaceuticals Quarterly report: Q2 2026
Emcure Pharmaceuticals has published its Q2 2026 quarterly earnings report on November 11, 2025.
Emcure Pharmaceuticals Transcript: Q1 25/26
Q1 FY2026 delivered strong growth with revenue up 15.7% and profit after tax up 41% year-over-year. Domestic and international segments both outperformed, with new product launches and partnerships driving momentum. EBITDA margin improved to 19.2%.
Emcure Pharmaceuticals Quarterly report: Q1 2026
Emcure Pharmaceuticals has published its Q1 2026 quarterly earnings report on August 7, 2025.